Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06125236

Registration of Acute Ischemic Stroke With Large and Medium-sized Vascular Occlusion in Southwest China(LMVOS)

This study is designed to observe the treatment options in real-world clinical practice as well as the safety and efficacy of different treatment strategies.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Ischemic Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Ischemic Stroke Nervous System Diseases Stroke Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Affiliated Hospital of Southwest Medical University

Luzhou, 646000, China

Location status: Recruiting

Location contact

Zhengzhou Yuan

CONTACT

+868303165661

About this study

LMVOS is a prospective, real-world registry lasting for 22 years. A total of 8000 patients with large- or medium-vessel occlusion will be enrolled.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The clinical diagnosis is acute ischemic stroke with large- or medium- vessel occlusion (the criteria followed the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018).

Informed consent from the patient or surrogate.

Exclusion criteria

No additional exclusion criteria.

Treatment and study plan

Visit at D90

Other

Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.

Primary outcomes

  1. modified Rankin Scale (mRS) score

    Time frame: 90±7 days

    Ordinal distribution of mRS at 90±7 days; modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)

Secondary outcomes

  1. Excellent functional outcome

    Time frame: 90±7 days

    Proportion of subjects with mRS 0-1 at 90±7 days.

  2. Good functional outcome

    Time frame: 90±7 days

    Proportion of subjects with mRS 0-2 at 90±7 days.

  3. mRS 0-3

    Time frame: 90±7 days

    Proportion of subjects with mRS 0-3 at 90±7 days.

  4. Change of National Institutes of Health Stroke Scale (NIHSS)

    Time frame: 24 hours

    Change of National Institutes of Health Stroke Scale (NIHSS, a scale between 0 and 42 on which higher scores indicate more severe neurologic deficits) from baseline to 24 hours.

  5. Change of National Institutes of Health Stroke Scale (NIHSS)

    Time frame: 7 days

    Change of National Institutes of Health Stroke Scale (NIHSS, a scale between 0 and 42 on which higher scores indicate more severe neurologic deficits) from baseline to 7 days.

  6. Symptom-to-thrombolysis time (STT)

    Time frame: 24 hours

    Time from onset of symptoms to thrombolytic therapy.

  7. Door-to-Needle Time

    Time frame: 24 hours

    Time from the arrival of stroke patient in emergency to initiation of thrombolysis therapy.

  8. Door-to-Puncture Time (DPT)

    Time frame: 24 hours

    ime from the arrival of stroke patient in emergency to groin puncture.

  9. Onset-to-recanalization time

    Time frame: 24 hours

    Time from symptom onset to the beginning of recanalization (recanalization defined as expanded TICI scale≥2b).

  10. Door-to-Recanalization Time (DRT)

    Time frame: 24 hours

    Time from the arrival of stroke patient in emergency to the beginning of recanalization (recanalization defined as expanded TICI scale≥2b).

  11. Puncture-to-recanalization time

    Time frame: 24 hours

    Time from groin puncture to recanalization (recanalization defined as expanded TICI scale≥2b).

Other outcomes

  1. Incidence of clinically significant intracranial hemorrhage

    Time frame: 36 hours

    Incidence of sICH (Heidelberg criteria) measured at 36 hours

  2. Incidence of any intracranial hemorrhage

    Time frame: 36 hours

    Incidence of any intracranial hemorrhage (Heidelberg criteria) measured at 36 hours

  3. All-cause mortality

    Time frame: 90±7 days

    All-cause mortality at 90±7 days

  4. Complications related to intravenous thrombolysis

    Time frame: up to 7 days

    Complications related to intravenous thrombolysis during hospitalization

  5. Complications related to endovascular treatment

    Time frame: up to 7 days

    Complications related to intravenous thrombolysis during hospitalization

Study contacts

Contact information is provided by the study sponsor or research team.

Zhengzhou Yuan, MD

CONTACT

[email protected]

+868303165661

Sponsors and collaborators

Lead sponsor

Zhengzhou Yuan

Other

Registry information

Acronym: LMVOS

Important dates

Study start
2023
Primary completion
2045
Study completion
2046
First posted
Nov 9, 2023
Registry last updated
Nov 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.